Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H17N2O5S.K |
Molecular Weight | 388.48 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[K+].[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COC3=CC=CC=C3)C([O-])=O
InChI
InChIKey=HCTVWSOKIJULET-LQDWTQKMSA-M
InChI=1S/C16H18N2O5S.K/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9;/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22);/q;+1/p-1/t11-,12+,14-;/m1./s1
Molecular Formula | K |
Molecular Weight | 39.0983 |
Charge | 1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C16H17N2O5S |
Molecular Weight | 349.382 |
Charge | -1 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB00417Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00417
Curator's Comment: Description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064071s006lbl.pdf
Penicillin V is a penicillin beta-lactam antibiotic used in the treatment of bacterial infections caused by susceptible, usually gram-positive, organisms. The name "penicillin" can either refer to several variants of penicillin available, or to the group of antibiotics derived from the penicillins. Penicillin V has in vitro activity against gram-positive and gram-negative aerobic and anaerobic bacteria. The bactericidal activity of Penicillin V results from the inhibition of cell wall synthesis and is mediated through Penicillin V binding to penicillin binding proteins (PBPs). Penicillin V is stable against hydrolysis by a variety of beta-lactamases, including penicillinases, and cephalosporinases and extended spectrum beta-lactamases. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, Penicillin V inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that Penicillin V interferes with an autolysin inhibitor. Used for the treatment of mild to moderately severe infections (e.g. dental infection, infections in the heart, middle ear infections, rheumatic fever, scarlet fever, skin infections, upper and lower respiratory tract infections) due to microorganisms.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL352 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16495241 |
|||
Target ID: Q8XJ01 Gene ID: 990276.0 Gene Symbol: pbpA Target Organism: Clostridium perfringens (strain 13 / Type A) Sources: http://www.drugbank.ca/drugs/DB00417 |
|||
Target ID: CHEMBL3512 Sources: http://www.drugbank.ca/drugs/DB00417 |
|||
Target ID: CHEMBL347 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3172134 |
|||
Target ID: CHEMBL2354204 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Penicillin V Approved UsePenicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response.
The following infections will usually respond to adequate dosage of Penicillin V.
Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas.
Pneumococcal infections. Mild to moderately severe infections of the respiratory tract.
Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues.
Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. Launch Date1990 |
|||
Curative | Penicillin V Approved UsePenicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response.
The following infections will usually respond to adequate dosage of Penicillin V.
Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas.
Pneumococcal infections. Mild to moderately severe infections of the respiratory tract.
Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues.
Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. Launch Date1990 |
|||
Curative | Penicillin V Approved UsePenicillin V potassium tablets and Penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response.
The following infections will usually respond to adequate dosage of Penicillin V.
Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas.
Pneumococcal infections. Mild to moderately severe infections of the respiratory tract.
Staphylococcal infections—penicillin G-sensitive. Mild infections of the skin and soft tissues.
Fusospirochetosis (Vincent's gingivitis and pharyngitis)—Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. Launch Date1990 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219 |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
PENICILLIN V POTASSIUM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
26.3 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219 |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: |
PENICILLIN V POTASSIUM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
35.5 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219 |
3 g single, oral dose: 3 g route of administration: Oral experiment type: SINGLE co-administered: |
PENICILLIN V POTASSIUM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219 |
0.4 g single, oral dose: 0.4 g route of administration: Oral experiment type: SINGLE co-administered: |
PENICILLIN V POTASSIUM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
19.01 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219 |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
PENICILLIN V POTASSIUM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
33.36 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219 |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: |
PENICILLIN V POTASSIUM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
43.94 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219 |
3 g single, oral dose: 3 g route of administration: Oral experiment type: SINGLE co-administered: |
PENICILLIN V POTASSIUM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
6.89 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219 |
0.4 g single, oral dose: 0.4 g route of administration: Oral experiment type: SINGLE co-administered: |
PENICILLIN V POTASSIUM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.78 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219 |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
PENICILLIN V POTASSIUM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.91 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219 |
2 g single, oral dose: 2 g route of administration: Oral experiment type: SINGLE co-administered: |
PENICILLIN V POTASSIUM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1.05 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219 |
3 g single, oral dose: 3 g route of administration: Oral experiment type: SINGLE co-administered: |
PENICILLIN V POTASSIUM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
0.52 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6811219 |
0.4 g single, oral dose: 0.4 g route of administration: Oral experiment type: SINGLE co-administered: |
PENICILLIN V POTASSIUM serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20% |
unknown, oral |
PENICILLIN V POTASSIUM serum | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg/kg 4 times / day multiple, oral Recommended Dose: 10 mg/kg, 4 times / day Route: oral Route: multiple Dose: 10 mg/kg, 4 times / day Sources: Page: p.48 |
unhealthy, 1-12 n = 216 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 1-12 Sex: M+F Population Size: 216 Sources: Page: p.48 |
Disc. AE: Stomach cramps, Nausea... Other AEs: Diarrhea, Rash... AEs leading to discontinuation/dose reduction: Stomach cramps (0.46%) Other AEs:Nausea (0.46%) Diarrhea (0.8%) Sources: Page: p.48Rash (1.2%) Abdominal pain (0.8%) Infection (1.7%) Headache (1.2%) Vomiting (2.5%) Rhinitis (1.2%) Gastroenteritis (0.4%) Epistaxis (0.4%) Ear pain (2.1%) Cough increased (1.2%) Nausea (0.8%) |
250 mg 4 times / day multiple, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: Page: p.3A-25S |
unhealthy, 16+ n = 117 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 16+ Sex: M+F Population Size: 117 Sources: Page: p.3A-25S |
Disc. AE: Abdominal pain... AEs leading to discontinuation/dose reduction: Abdominal pain (1.7%) Sources: Page: p.3A-25S |
590 mg 3 times / day multiple, oral Recommended Dose: 590 mg, 3 times / day Route: oral Route: multiple Dose: 590 mg, 3 times / day Sources: Page: p.341 |
unhealthy, 28+/-7.9 n = 113 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 28+/-7.9 Sex: M+F Population Size: 113 Sources: Page: p.341 |
Disc. AE: Nausea, Taste alteration... AEs leading to discontinuation/dose reduction: Nausea (grade 3, 0.88%) Sources: Page: p.341Taste alteration (grade 3, 0.88%) |
800 mg 4 times / day multiple, oral Highest studied dose Dose: 800 mg, 4 times / day Route: oral Route: multiple Dose: 800 mg, 4 times / day Sources: |
unhealthy, 30.0 (6–73) n = 212 Health Status: unhealthy Condition: Pharyngotonsillitis caused by group A streptococci Age Group: 30.0 (6–73) Sex: M+F Population Size: 212 Sources: |
|
1 g 3 times / day multiple, oral Recommended Dose: 1 g, 3 times / day Route: oral Route: multiple Dose: 1 g, 3 times / day Sources: |
unhealthy, 31.0 (3–67) n = 210 Health Status: unhealthy Condition: Pharyngotonsillitis caused by group A streptococci Age Group: 31.0 (3–67) Sex: M+F Population Size: 210 Sources: |
|
3 g multiple, oral Recommended Dose: 3 g Route: oral Route: multiple Dose: 3 g Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Prophylaxis against bacterial endocarditis Sources: Page: p.2 |
|
250 mg 4 times / day multiple, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: Page: p.70/306 |
unhealthy n = 175 Health Status: unhealthy Condition: Streptococcal pharyngitis|Streptococcal tonsillitis Sex: M+F Population Size: 175 Sources: Page: p.70/306 |
Disc. AE: Rash, Vomiting... AEs leading to discontinuation/dose reduction: Rash (0.57%) Sources: Page: p.70/306Vomiting (0.57%) |
500 mg 4 times / day multiple, oral (max) Recommended Dose: 500 mg, 4 times / day Route: oral Route: multiple Dose: 500 mg, 4 times / day Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Infections due to penicillin G sensitive microorganisms Sources: Page: p.2 |
Disc. AE: Hypersensitivity reaction, Diarrhea, Clostridium difficile... AEs leading to discontinuation/dose reduction: Hypersensitivity reaction (serious|grade 5) Sources: Page: p.2Diarrhea, Clostridium difficile (mild|grade 5) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Epistaxis | 0.4% | 10 mg/kg 4 times / day multiple, oral Recommended Dose: 10 mg/kg, 4 times / day Route: oral Route: multiple Dose: 10 mg/kg, 4 times / day Sources: Page: p.48 |
unhealthy, 1-12 n = 216 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 1-12 Sex: M+F Population Size: 216 Sources: Page: p.48 |
Gastroenteritis | 0.4% | 10 mg/kg 4 times / day multiple, oral Recommended Dose: 10 mg/kg, 4 times / day Route: oral Route: multiple Dose: 10 mg/kg, 4 times / day Sources: Page: p.48 |
unhealthy, 1-12 n = 216 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 1-12 Sex: M+F Population Size: 216 Sources: Page: p.48 |
Nausea | 0.46% Disc. AE |
10 mg/kg 4 times / day multiple, oral Recommended Dose: 10 mg/kg, 4 times / day Route: oral Route: multiple Dose: 10 mg/kg, 4 times / day Sources: Page: p.48 |
unhealthy, 1-12 n = 216 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 1-12 Sex: M+F Population Size: 216 Sources: Page: p.48 |
Stomach cramps | 0.46% Disc. AE |
10 mg/kg 4 times / day multiple, oral Recommended Dose: 10 mg/kg, 4 times / day Route: oral Route: multiple Dose: 10 mg/kg, 4 times / day Sources: Page: p.48 |
unhealthy, 1-12 n = 216 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 1-12 Sex: M+F Population Size: 216 Sources: Page: p.48 |
Abdominal pain | 0.8% | 10 mg/kg 4 times / day multiple, oral Recommended Dose: 10 mg/kg, 4 times / day Route: oral Route: multiple Dose: 10 mg/kg, 4 times / day Sources: Page: p.48 |
unhealthy, 1-12 n = 216 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 1-12 Sex: M+F Population Size: 216 Sources: Page: p.48 |
Diarrhea | 0.8% | 10 mg/kg 4 times / day multiple, oral Recommended Dose: 10 mg/kg, 4 times / day Route: oral Route: multiple Dose: 10 mg/kg, 4 times / day Sources: Page: p.48 |
unhealthy, 1-12 n = 216 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 1-12 Sex: M+F Population Size: 216 Sources: Page: p.48 |
Nausea | 0.8% | 10 mg/kg 4 times / day multiple, oral Recommended Dose: 10 mg/kg, 4 times / day Route: oral Route: multiple Dose: 10 mg/kg, 4 times / day Sources: Page: p.48 |
unhealthy, 1-12 n = 216 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 1-12 Sex: M+F Population Size: 216 Sources: Page: p.48 |
Cough increased | 1.2% | 10 mg/kg 4 times / day multiple, oral Recommended Dose: 10 mg/kg, 4 times / day Route: oral Route: multiple Dose: 10 mg/kg, 4 times / day Sources: Page: p.48 |
unhealthy, 1-12 n = 216 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 1-12 Sex: M+F Population Size: 216 Sources: Page: p.48 |
Headache | 1.2% | 10 mg/kg 4 times / day multiple, oral Recommended Dose: 10 mg/kg, 4 times / day Route: oral Route: multiple Dose: 10 mg/kg, 4 times / day Sources: Page: p.48 |
unhealthy, 1-12 n = 216 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 1-12 Sex: M+F Population Size: 216 Sources: Page: p.48 |
Rash | 1.2% | 10 mg/kg 4 times / day multiple, oral Recommended Dose: 10 mg/kg, 4 times / day Route: oral Route: multiple Dose: 10 mg/kg, 4 times / day Sources: Page: p.48 |
unhealthy, 1-12 n = 216 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 1-12 Sex: M+F Population Size: 216 Sources: Page: p.48 |
Rhinitis | 1.2% | 10 mg/kg 4 times / day multiple, oral Recommended Dose: 10 mg/kg, 4 times / day Route: oral Route: multiple Dose: 10 mg/kg, 4 times / day Sources: Page: p.48 |
unhealthy, 1-12 n = 216 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 1-12 Sex: M+F Population Size: 216 Sources: Page: p.48 |
Infection | 1.7% | 10 mg/kg 4 times / day multiple, oral Recommended Dose: 10 mg/kg, 4 times / day Route: oral Route: multiple Dose: 10 mg/kg, 4 times / day Sources: Page: p.48 |
unhealthy, 1-12 n = 216 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 1-12 Sex: M+F Population Size: 216 Sources: Page: p.48 |
Ear pain | 2.1% | 10 mg/kg 4 times / day multiple, oral Recommended Dose: 10 mg/kg, 4 times / day Route: oral Route: multiple Dose: 10 mg/kg, 4 times / day Sources: Page: p.48 |
unhealthy, 1-12 n = 216 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 1-12 Sex: M+F Population Size: 216 Sources: Page: p.48 |
Vomiting | 2.5% | 10 mg/kg 4 times / day multiple, oral Recommended Dose: 10 mg/kg, 4 times / day Route: oral Route: multiple Dose: 10 mg/kg, 4 times / day Sources: Page: p.48 |
unhealthy, 1-12 n = 216 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 1-12 Sex: M+F Population Size: 216 Sources: Page: p.48 |
Abdominal pain | 1.7% Disc. AE |
250 mg 4 times / day multiple, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: Page: p.3A-25S |
unhealthy, 16+ n = 117 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 16+ Sex: M+F Population Size: 117 Sources: Page: p.3A-25S |
Nausea | grade 3, 0.88% Disc. AE |
590 mg 3 times / day multiple, oral Recommended Dose: 590 mg, 3 times / day Route: oral Route: multiple Dose: 590 mg, 3 times / day Sources: Page: p.341 |
unhealthy, 28+/-7.9 n = 113 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 28+/-7.9 Sex: M+F Population Size: 113 Sources: Page: p.341 |
Taste alteration | grade 3, 0.88% Disc. AE |
590 mg 3 times / day multiple, oral Recommended Dose: 590 mg, 3 times / day Route: oral Route: multiple Dose: 590 mg, 3 times / day Sources: Page: p.341 |
unhealthy, 28+/-7.9 n = 113 Health Status: unhealthy Condition: Streptococcal Pharyngitis Age Group: 28+/-7.9 Sex: M+F Population Size: 113 Sources: Page: p.341 |
Rash | 0.57% Disc. AE |
250 mg 4 times / day multiple, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: Page: p.70/306 |
unhealthy n = 175 Health Status: unhealthy Condition: Streptococcal pharyngitis|Streptococcal tonsillitis Sex: M+F Population Size: 175 Sources: Page: p.70/306 |
Vomiting | 0.57% Disc. AE |
250 mg 4 times / day multiple, oral Recommended Dose: 250 mg, 4 times / day Route: oral Route: multiple Dose: 250 mg, 4 times / day Sources: Page: p.70/306 |
unhealthy n = 175 Health Status: unhealthy Condition: Streptococcal pharyngitis|Streptococcal tonsillitis Sex: M+F Population Size: 175 Sources: Page: p.70/306 |
Diarrhea, Clostridium difficile | mild|grade 5 Disc. AE |
500 mg 4 times / day multiple, oral (max) Recommended Dose: 500 mg, 4 times / day Route: oral Route: multiple Dose: 500 mg, 4 times / day Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Infections due to penicillin G sensitive microorganisms Sources: Page: p.2 |
Hypersensitivity reaction | serious|grade 5 Disc. AE |
500 mg 4 times / day multiple, oral (max) Recommended Dose: 500 mg, 4 times / day Route: oral Route: multiple Dose: 500 mg, 4 times / day Sources: Page: p.2 |
unhealthy Health Status: unhealthy Condition: Infections due to penicillin G sensitive microorganisms Sources: Page: p.2 |
PubMed
Title | Date | PubMed |
---|---|---|
Assessment of the "E' book as a tool for drug monitoring. | 1981 Mar |
|
A systematic review of antistreptococcal interventions for guttate and chronic plaque psoriasis. | 2001 Dec |
|
Biphasic illness pattern due to early relapse in Japanese-B virus encephalitis. | 2001 Jan 15 |
|
Paediatric antibiotic prescribing by general dental practitioners in England. | 2001 Jul |
|
Determination of benzylpenicillin, oxacillin, cloxacillin, and dicloxacillin in cows' milk by ion-pair high-performance liquid chromatography after precolumn derivatization. | 2001 Sep |
|
Fine structural recognition specificities of IgE antibodies distinguishing amoxicilloyl and amoxicillanyl determinants in allergic subjects. | 2001 Sep-Oct |
|
Antibiotic prescribing in outpatients: a 1-week diagnosis-prescribing study in 5 counties in Sweden. | 2002 |
|
Birth outcome of 1886 pregnancies after exposure to phenoxymethylpenicillin in utero. | 2002 Apr |
|
Solitary erythema migrans in children: comparison of treatment with azithromycin and phenoxymethylpenicillin. | 2002 Jul 31 |
|
Liquid chromatographic determination of ampicillin residues in porcine muscle tissue by a multipenicillin analytical method: European Collaborative Study. | 2002 Jul-Aug |
|
Substrate specificity of penicillin acylase from Streptomyces lavendulae. | 2002 Mar 1 |
|
Clinical outcome of erythema migrans after treatment with phenoxymethyl penicillin. | 2003 |
|
Telithromycin: new preparation. A needless addition to the other macrolides. | 2003 Feb |
|
Data from electronic patient records are suitable for surveillance of antibiotic prescriptions for respiratory tract infections in primary health care. | 2004 |
|
Acute sinusitis: guide to selection of antibacterial therapy. | 2004 |
|
Antibiotics for acute group A streptococcal pharyngitis. | 2004 Dec |
|
[Prevention and infection in adults patients with hyposplenism]. | 2004 Nov |
|
Tick-borne encephalopathies : epidemiology, diagnosis, treatment and prevention. | 2005 |
|
Antigen specific quantification of sulfidoleukotrienes in patients allergic to Betalactam antibiotics. | 2005 |
|
Community prescribing and resistant Streptococcus pneumoniae. | 2005 Jun |
|
Comparative bioavailability study of two phenoxymethylpenicillin potassium tablet formulations in healthy volunteers. | 2007 Dec |
|
Aminopenicillin-induced exanthema allows treatment with certain cephalosporins or phenoxymethyl penicillin. | 2007 Jul |
|
Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption. | 2007 Jun |
|
Association of IL-10 level and IL-10 promoter SNPs with specific antibodies in penicillin-allergic patients. | 2007 Mar |
|
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. | 2008 Aug |
|
Effects of treatment with antimicrobial agents on the human colonic microflora. | 2008 Dec |
|
[Summary of the practice guideline 'Sore throat' (second revision) from the Dutch College of General Practitioners]. | 2008 Feb 23 |
|
Challenges of cellulitis in a lymphedematous extremity: a case report. | 2009 Dec 22 |
|
Acute tonsillopharyngitis in a family practice in Mostar, Bosnia and Herzegovina. | 2009 Mar |
|
Synthesis of novel hapten and production of generic monoclonal antibody for immunoassay of penicillins residues in milk. | 2013 |
Patents
Sample Use Guides
Usual Adult Dose for Bacterial Infection
Mild to moderate infections: 125 to 500 mg orally every 6 to 8 hours
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16495241
Penicillin V inhibited Staphylococcus aureus in human THP-1 macrophages (intracellular) with MIC90 of 0.015 mg/L
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:03:29 GMT 2023
by
admin
on
Fri Dec 15 16:03:29 GMT 2023
|
Record UNII |
146T0TU1JB
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1500
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
132-98-9
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY | |||
|
m8479
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
146T0TU1JB
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY | |||
|
7967
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY | |||
|
203195
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY | RxNorm | ||
|
1504503
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY | |||
|
6315
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY | |||
|
DBSALT000299
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY | |||
|
PENICILLIN V POTASSIUM
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY | Description: A white or almost white, crystalline powder; odourless or with a faint characteristic odour. Solubility: Soluble in about 1.5 parts of water; practically insoluble in ether R. Category: Antibiotic. Storage: Phenoxymethylpenicillin potassium should be kept in a tightly closed container; protected from light. Additional information: Even in the absence of light, Phenoxymethylpenicillin potassium is gradually degraded on exposure to ahumid atmosphere, the decomposition being faster at higher temperatures. Definition: Phenoxymethylpenicillin potassium contains not less than 95.0% and not more than 102.0% of C16H17KN2O5S,calculated with reference to the dried substance. | ||
|
SUB03766MIG
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY | |||
|
100000090273
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY | |||
|
757258
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY | |||
|
C730
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY | |||
|
146T0TU1JB
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY | |||
|
205-086-5
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY | |||
|
DTXSID7021102
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY | |||
|
23676814
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL615
Created by
admin on Fri Dec 15 16:03:30 GMT 2023 , Edited by admin on Fri Dec 15 16:03:30 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
Elimination PHARMACOKINETIC |
|
||